| Study Period | 2019 - 2032 |
| Market Size in 2024 | USD 131.9 Million |
| Market Size in 2025 | USD 146.1 Million |
| Market Size by 2032 | USD 318.5 Million |
| Projected CAGR | 11.8% |
| Largest Region | North America |
| Fastest Growing Region | APAC |
| Market Structure | Conslidated |
Explore the market potential with our data-driven report
The global endoluminal suturing devices market was valued at USD 131.9 million in 2024 and is projected to grow at a CAGR of 11.8% during 2025–2032, reaching USD 318.5 million by 2032. The market growth is driven by the rising prevalence of obesity and gastrointestinal disorders, increasing adoption of minimally invasive surgical procedures, and technological advancements in endoscopic suturing systems.
The growing global obesity epidemic has significantly contributed to market expansion. According to the World Health Organization, more than 1 billion people worldwide were obese in 2024, including 880 million adults and 159 million children and adolescents aged 5–19 years. This alarming statistic underscores the urgent need for minimally invasive bariatric interventions, where endoluminal suturing devices play a crucial role in procedures such as endoscopic sleeve gastroplasty and revision surgeries.
The market is also benefiting from the increasing prevalence of gastroesophageal reflux disease, which affects approximately 14% of the global population, creating substantial demand for endoluminal interventions. Healthcare providers increasingly prioritize patient safety and improved surgical outcomes through minimally invasive approaches, positioning endoluminal suturing devices as essential tools for modern endoscopic procedures. The integration of these devices with robotic-assisted platforms and advanced imaging technologies has further enhanced their adoption across hospitals and ambulatory surgical centers worldwide.
The integration of robot-assisted technologies with endoluminal suturing devices represents a significant trend reshaping the market landscape. Advanced robotic platforms are increasingly being combined with endoscopic suturing systems to enhance precision, reduce surgeon fatigue, and improve procedural outcomes. These integrated solutions provide surgeons with enhanced dexterity through articulated instruments that can mimic natural wrist movements while offering three-dimensional visualization and tremor filtration capabilities. The technology enables more complex endoluminal procedures to be performed with greater accuracy and consistency compared to traditional manual techniques.
Major medical device manufacturers are investing heavily in developing robotic-compatible endoluminal suturing platforms that can seamlessly integrate with existing surgical robotic systems. These innovations are particularly valuable in challenging anatomical locations where manual dexterity is limited, such as deep pelvic procedures or complex gastroesophageal junction repairs. The enhanced visualization and precise instrument control provided by robotic assistance allow surgeons to perform full-thickness suturing with improved tissue approximation and reduced risk of complications.
The adoption of robotic-assisted endoluminal suturing is gaining momentum in leading medical centers worldwide, with hospitals recognizing the potential for improved patient outcomes and operational efficiency. Training programs are being developed to help surgeons transition to these advanced platforms, while clinical studies continue to demonstrate superior outcomes compared to conventional endoscopic techniques. This technological convergence is expected to drive premium pricing for advanced systems while expanding the total addressable market for endoluminal suturing devices.
The trend toward robotic integration is also creating new competitive dynamics, with companies forming strategic partnerships with robotic surgical platform manufacturers to develop comprehensive solutions. This collaboration approach is accelerating innovation cycles and enabling more rapid market penetration of advanced endoluminal suturing technologies across diverse surgical specialties.
The escalating global obesity crisis represents the primary driver for the endoluminal suturing devices market expansion. According to the World Obesity Federation, the worldwide prevalence of obesity has more than tripled between 1975 and 2022, with nearly three billion people now living with either overweight or obesity. The Centers for Disease Control and Prevention reports that 40.3% of the adults in the U.S. were obese during August 2021–August 2023, creating an enormous patient population requiring bariatric interventions.
Endoluminal suturing devices are increasingly utilized in minimally invasive bariatric procedures, such as endoscopic sleeve gastroplasty and transoral outlet reduction, offering effective weight management solutions with reduced procedural risks compared to traditional open surgeries. The devices enable surgeons to perform complex gastric remodeling procedures through natural orifices, eliminating the need for external incisions and significantly reducing recovery times. This technological advancement aligns with patient preferences for less invasive treatment options while maintaining clinical efficacy in achieving sustainable weight loss outcomes.
The shortage of skilled surgeons trained in advanced endoluminal suturing techniques represents a significant challenge limiting market growth potential. Endoluminal suturing procedures require specialized training and extensive experience to achieve optimal outcomes, as the techniques involve complex instrument manipulation within confined anatomical spaces. The learning curve for mastering these procedures is considerably steeper than traditional endoscopic interventions, requiring dedicated training programs and ongoing practice to maintain proficiency.
According to healthcare workforce studies, the supply of gastroenterologists and bariatric surgeons with advanced endoscopic skills is not keeping pace with growing demand for minimally invasive procedures. This skill gap is particularly pronounced in emerging markets and rural healthcare settings, where access to specialized training programs may be limited. The complexity of endoluminal suturing procedures means that even experienced endoscopists require additional training to safely and effectively utilize these advanced devices.
The single-use devices category held the larger share in the endoluminal suturing devices market in 2024, of 65%, and it is expected to maintain its dominant position throughout the forecast period. This dominance is primarily attributed to the growing emphasis on infection control and patient safety, as single-use devices eliminate risks associated with cross-contamination and surgical site infections. Healthcare institutions increasingly prefer disposable endoluminal suturing devices due to their convenience in handling and storage, elimination of sterilization requirements, and consistent performance characteristics that reduce procedural variability.
Reusable devices are expected to witness the faster growth during 2025–2032, driven by cost-conscious healthcare environments and improved device durability technologies. Advanced reusable endoluminal suturing systems offer economic advantages for high-volume surgical centers while incorporating enhanced cleaning and sterilization protocols that ensure patient safety. The category benefits from technological innovations in device materials and design that extend operational lifespans and maintain precision suturing capabilities across multiple procedures, making them attractive options for resource-optimized healthcare settings.
These product types are covered:
The gastrointestinal surgery category accounted for the largest share in 2024, of 40%, due to the high prevalence of gastrointestinal disorders requiring endoscopic interventions. This category benefits from the growing incidence of gastroesophageal reflux disease, peptic ulcers, and gastrointestinal perforations, which require precise tissue approximation and defect closure. Endoluminal suturing devices are extensively used in endoscopic mucosal resection, perforation closure, and anti-reflux therapies, providing surgeons with advanced tools for comprehensive gastrointestinal care.
The bariatric surgery category is projected to exhibit the fastest growth during the forecast period, driven by the global obesity epidemic and increasing acceptance of minimally invasive weight loss procedures. Endoluminal suturing devices play a crucial role in bariatric endoscopy applications, including endoscopic sleeve gastroplasty, transoral outlet reduction, and revision procedures for patients who have experienced weight regain after initial bariatric surgery. The category growth is supported by favorable reimbursement policies and expanding physician training programs in endoscopic bariatric techniques.
These applications are covered:
The needle category commanded the largest market share, of approximately 45%, in 2024. Needles are critical components that directly impact suturing precision and tissue penetration capabilities, making them essential elements in endoluminal suturing procedures. Advanced needle technologies incorporate specialized tip designs, enhanced visibility features, and improved flexibility that enable surgeons to navigate complex anatomical structures with greater accuracy and control.
The cannula category is projected to witness the fastest growth due to its role in facilitating device deployment and tissue manipulation during endoluminal procedures. Modern cannula designs feature improved ergonomics and enhanced visualization capabilities that support more efficient suturing workflows. The suction port category, while smaller in market share, remains crucial for maintaining clear visualization fields and optimizing procedural outcomes through effective fluid management during endoscopic interventions.
These components are covered:
The hospitals category held the largest market share, of approximately 60%, in 2024, attributed to their comprehensive infrastructure for complex endoscopic procedures and availability of specialized gastroenterology departments. Hospitals serve as primary centers for advanced surgical interventions, possessing the necessary equipment, skilled personnel, and support systems required for endoluminal suturing procedures. The category benefits from high patient volumes, emergency procedure capabilities, and integration with robotic-assisted surgical platforms that enhance procedural precision and outcomes.
Ambulatory surgical centers are expected to exhibit the fastest growth during the forecast period, driven by the shift toward outpatient procedures and cost-effective healthcare delivery models. These facilities offer specialized endoscopic services in controlled environments while providing significant cost savings compared to traditional hospital settings. The category growth is supported by improved reimbursement policies for outpatient procedures and increasing patient preferences for same-day discharge options following minimally invasive interventions.
These end users are covered:
Drive strategic growth with comprehensive market analysis
North America held the largest share, of approximately 45%, in 2024, and it is expected to maintain its position throughout the forecast period. The region's dominance is primarily attributed to its well-established healthcare infrastructure, high healthcare expenditure, and strong adoption rates of advanced medical technologies. The U.S. represents the largest market within the region, driven by the high prevalence of obesity and gastrointestinal disorders requiring endoscopic interventions.
According to the Centers for Disease Control and Prevention, approximately 40.3% of the American adults are obese, creating a substantial patient population for bariatric endoscopy procedures. The region benefits from favorable reimbursement policies for minimally invasive procedures, extensive physician training programs, and the presence of leading medical device manufacturers. Advanced healthcare systems in countries like the U.S. and Canada have readily integrated endoluminal suturing devices into routine clinical practice, supporting consistent market growth.
The regulatory environment in North America, particularly FDA approvals and clinical guidelines, has facilitated the rapid adoption of innovative endoluminal suturing technologies. Major healthcare institutions across the region have invested in comprehensive endoscopy programs that incorporate advanced suturing capabilities, positioning North America as a key growth driver for the global market.
Asia-Pacific is expected to be the fastest-growing regional market, with a CAGR of 12.1%, during 2025–2032. The region's rapid growth is driven by improving healthcare infrastructure, increasing disposable incomes, and growing awareness of minimally invasive surgical options. China, Japan, and India represent significant opportunities due to their large patient populations and expanding healthcare systems.
The rising prevalence of lifestyle-related diseases in Asia-Pacific, including obesity and gastrointestinal disorders, has created substantial demand for advanced endoscopic interventions. According to the World Health Organization, the region has experienced significant increases in obesity rates, particularly in urban populations adopting Western dietary patterns. Healthcare systems across Asia-Pacific are investing in advanced endoscopic technologies to address growing patient needs while managing healthcare costs through minimally invasive approaches.
Government initiatives promoting healthcare modernization and medical tourism in countries like South Korea, Thailand, and Singapore have accelerated the adoption of advanced medical technologies, including endoluminal suturing devices. The region's focus on healthcare digitalization and integration of robotic-assisted surgical systems provides additional growth opportunities for endoluminal suturing device manufacturers.
These regions and countries are covered:
The endoluminal suturing devices market exhibits a consolidated competitive structure, with the top five key players collectively holding a more than 55% market share in 2024. This consolidation reflects the specialized nature of endoluminal suturing technology and the significant barriers to entry, including complex regulatory requirements, substantial R&D investments, and the need for extensive clinical validation. The market leaders have established strong positions through comprehensive product portfolios, robust distribution networks, and strategic partnerships with healthcare institutions.
Apollo Endosurgery holds the largest market share of approximately 30% in 2024, primarily due to its OverStitch endoscopic suturing system, which has become the gold standard for endoluminal suturing procedures. The company's dominance is supported by extensive clinical data, broad regulatory approvals, and strong physician adoption rates across multiple therapeutic applications. Following Boston Scientific's acquisition of Apollo Endosurgery in November 2022, the combined entity has strengthened its position through enhanced global distribution capabilities and expanded product development resources.
Key competitive strategies in the market include continuous product innovation, strategic acquisitions, and expansion into emerging markets. Leading companies are investing in next-generation suturing technologies that offer improved precision, enhanced visualization, and compatibility with robotic surgical systems. Partnership agreements with healthcare institutions and medical societies provide platforms for clinical education and product validation, supporting broader market adoption.
The market presents opportunities for new entrants in specialized applications such as pediatric endoscopy and emerging therapeutic areas where current solutions may have limitations. However, established players maintain competitive advantages through patent portfolios, regulatory expertise, and established clinical relationships that create significant challenges for market disruption.
Major companies operating in the market include Apollo Endosurgery (Boston Scientific), Medtronic, Johnson & Johnson (Ethicon), Cook Group, USGI Medical, Ovesco Endoscopy AG, Endo Tools Therapeutics, ErgoSuture, Sutrue Ltd., and Olympus Corporation.
Want a report tailored exactly to your business need?
Request CustomizationLeading companies across industries trust us to deliver data-driven insights and innovative solutions for their most critical decisions. From data-driven strategies to actionable insights, we empower the decision-makers who shape industries and define the future. From Fortune 500 companies to innovative startups, we are proud to partner with organisations that drive progress in their industries.
Working with P&S Intelligence and their team was an absolute pleasure – their awareness of timelines and commitment to value greatly contributed to our project's success. Eagerly anticipating future collaborations.
McKinsey & Company
India
Our insights into the minutest levels of the markets, including the latest trends and competitive landscape, give you all the answers you need to take your business to new heights
We take a cautious approach to protecting your personal and confidential information. Trust is the strongest bond that connects us and our clients, and trust we build by complying with all international and domestic data protection and privacy laws
Customize the Report to Align with Your Business Objectives
Request the Free Sample Pages